foscarnet has been researched along with Viral Diseases in 15 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The DNA polymerase of human herpes viruses, including cytomegalovirus (CMV), and the reverse transcriptase of human immunodeficiency virus (HIV) are selectively inhibited in vitro by the pyrophosphate analogue foscarnet." | 6.17 | Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. ( Bryson, HM; Wagstaff, AJ, 1994) |
| " Herpes virus type 1 and rarely type 2 may lead to painful and resistant oral ulcers, and systemic treatment with acyclovir, valaciclovir or famciclovir is indicated." | 4.79 | Viral lesions of the mouth in HIV-infected patients. ( Itin, PH; Lautenschlager, S, 1997) |
| " These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms." | 2.66 | Antiviral chemotherapy and chemoprophylaxis. ( Dolin, R, 1985) |
| " In paediatric patients this may be difficult to achieve due to lack of pharmacokinetic studies, administration of small doses, changes in body composition, continuous growth, and development and maturation of organs and systems." | 2.42 | The pharmacokinetics of antiviral therapy in paediatric patients. ( Eksborg, S, 2003) |
| " In patients with renal insufficiency, careful dosage adjustment is mandatory to optimize drug exposure and reduce the risk for adverse events." | 2.41 | Anti-viral drugs in continuous ambulatory peritoneal dialysis (CAPD). ( Deray, G; Issad, B; Izzedine, H; Launay-Vacher, V, 2002) |
| "Several new agents for treating viral infections have been developed in recent years." | 2.40 | Antiviral agents for non-human immunodeficiency virus infections. ( Keating, MR, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (26.67) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kuwatsuka, Y | 1 |
| Atsuta, Y | 1 |
| Hirakawa, A | 1 |
| Uchida, N | 1 |
| Inamoto, Y | 1 |
| Najima, Y | 1 |
| Ikegame, K | 1 |
| Eto, T | 1 |
| Ozawa, Y | 1 |
| Ichinohe, T | 1 |
| Inoue, M | 1 |
| Kimura, T | 1 |
| Okamoto, S | 1 |
| Miyamura, K | 1 |
| Fukuda, T | 1 |
| Eksborg, S | 1 |
| Angarone, M | 1 |
| Ison, MG | 1 |
| Brochier, B | 1 |
| Thiry, E | 1 |
| Wérenne, J | 1 |
| Schwers, A | 1 |
| Vindevogel, H | 1 |
| Pastoret, PP | 1 |
| Wagstaff, AJ | 1 |
| Bryson, HM | 1 |
| Itin, PH | 1 |
| Lautenschlager, S | 1 |
| Keating, MR | 1 |
| Izzedine, H | 1 |
| Launay-Vacher, V | 1 |
| Issad, B | 1 |
| Deray, G | 1 |
| Seigneurin, JM | 1 |
| Smyth, RL | 1 |
| Scott, JP | 1 |
| Borysiewicz, LK | 1 |
| Sharples, LD | 1 |
| Stewart, S | 1 |
| Wreghitt, TG | 1 |
| Gray, JJ | 1 |
| Higenbottam, TW | 1 |
| Wallwork, J | 1 |
| Oberg, B | 1 |
| Dolin, R | 1 |
8 reviews available for foscarnet and Viral Diseases
| Article | Year |
|---|---|
The pharmacokinetics of antiviral therapy in paediatric patients.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Child; Child, Hospitalized; Cidofovir; Cytosine; Famcicl | 2003 |
Prevention and early treatment of opportunistic viral infections in patients with leukemia and allogeneic stem cell transplantation recipients.
Topics: Antiviral Agents; Benzimidazoles; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Herpes Zoster; | 2008 |
[Etiological therapeutics in viral diseases].
Topics: Acyclovir; Amantadine; Animals; Antibodies, Viral; Antiviral Agents; Chemical Phenomena; Chemistry; | 1984 |
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus; Drug Administration Schedule; Drug Interacti | 1994 |
Viral lesions of the mouth in HIV-infected patients.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cytomegalovirus In | 1997 |
Antiviral agents for non-human immunodeficiency virus infections.
Topics: 2-Aminopurine; Acetamides; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Cytosine; Drug Resist | 1999 |
Anti-viral drugs in continuous ambulatory peritoneal dialysis (CAPD).
Topics: Adamantane; Anti-HIV Agents; Antimetabolites; Antiviral Agents; Dideoxynucleosides; Foscarnet; Hepat | 2002 |
Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
Topics: Adolescent; Adult; Animals; Antiviral Agents; Child; Female; Foscarnet; Guinea Pigs; Humans; Male; M | 1989 |
2 trials available for foscarnet and Viral Diseases
| Article | Year |
|---|---|
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus; Drug Administration Schedule; Drug Interacti | 1994 |
Antiviral chemotherapy and chemoprophylaxis.
Topics: Acyclovir; Adult; Aged; Amantadine; Antiviral Agents; Chickenpox; Clinical Trials as Topic; Cytomega | 1985 |
6 other studies available for foscarnet and Viral Diseases
| Article | Year |
|---|---|
Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection.
Topics: Acute Disease; Adult; Beclomethasone; Chronic Disease; Cidofovir; Cytomegalovirus Infections; Etaner | 2020 |
Drugs for non-HIV viral infections.
Topics: Acyclovir; Amantadine; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Ganciclovir; Humans; | 1994 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Abnormalities, Drug-Induced; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Cont | 1997 |
[Resistance of viruses to antiviral agents].
Topics: Acyclovir; Antiviral Agents; Drug Resistance; Foscarnet; Humans; Immunocompromised Host; Phosphonoac | 1992 |
Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment.
Topics: Adolescent; Adult; Antibodies, Viral; Bacterial Infections; Child; Cytomegalovirus; Cytomegalovirus | 1991 |
Foscarnet.
Topics: Animals; Antiviral Agents; Deltaretrovirus; Foscarnet; Humans; Organophosphorus Compounds; Phosphono | 1985 |